Inmune Bio Stock Alpha and Beta Analysis
| INMB Stock | USD 7.95 0.07 0.87% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as INmune Bio. It also helps investors analyze the systematic and unsystematic risks associated with investing in INmune Bio over a specified time horizon. Remember, high INmune Bio's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to INmune Bio's market risk premium analysis include:
Beta 0.67 | Alpha 0.92 | Risk 6.16 | Sharpe Ratio 0.14 | Expected Return 0.89 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
INmune |
INmune Bio Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. INmune Bio market risk premium is the additional return an investor will receive from holding INmune Bio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in INmune Bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate INmune Bio's performance over market.| α | 0.92 | β | 0.67 |
INmune Bio expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of INmune Bio's Buy-and-hold return. Our buy-and-hold chart shows how INmune Bio performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.INmune Bio Market Price Analysis
Market price analysis indicators help investors to evaluate how INmune Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading INmune Bio shares will generate the highest return on investment. By understating and applying INmune Bio stock market price indicators, traders can identify INmune Bio position entry and exit signals to maximize returns.
INmune Bio Return and Market Media
The median price of INmune Bio for the period between Wed, Dec 11, 2024 and Tue, Mar 11, 2025 is 6.72 with a coefficient of variation of 27.34. The daily time series for the period is distributed with a sample standard deviation of 1.89, arithmetic mean of 6.91, and mean deviation of 1.73. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Allen Marcia of 32500 shares of INmune Bio at 5.05 subject to Rule 16b-3 | 12/20/2024 |
2 | Acquisition by Lowdell Mark William of 14423 shares of INmune Bio at 8.32 subject to Rule 16b-3 | 12/31/2024 |
3 | Acquisition by Moss David J of 160000 shares of INmune Bio at 9.92 subject to Rule 16b-3 | 01/24/2025 |
4 | INmune Bio Rating Increased to Strong-Buy at RODMANRENSHAW - MarketBeat | 01/29/2025 |
5 | Acquisition by Xencor Inc of 192533 shares of INmune Bio at 17.14 subject to Rule 16b-3 | 01/30/2025 |
6 | Acquisition by Schroeder Timothy J of 12500 shares of INmune Bio at 9.92 subject to Rule 16b-3 | 01/31/2025 |
7 | Why INmune Bio Inc Is Skyrocketing So Far In 2025 - Yahoo Finance | 02/03/2025 |
8 | Why INmune Bio Inc Is Skyrocketing So Far In 2025 | 02/04/2025 |
9 | INmune Bio Announces Plan to Submit FDA Biologics License Application Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa | 02/10/2025 |
10 | INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer | 02/12/2025 |
11 | Acquisition by Baracchini Edgardo Jr of 35000 shares of INmune Bio subject to Rule 16b-3 | 03/05/2025 |
12 | Acquisition by Lowdell Mark William of 140000 shares of INmune Bio at 5.05 subject to Rule 16b-3 | 03/07/2025 |
About INmune Bio Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including INmune or other stocks. Alpha measures the amount that position in INmune Bio has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | |
| Interest Debt Per Share | 0.93 | 0.58 | 0.52 | 0.34 |
| Revenue Per Share | 0.0209 | 0.00862 | 0.009913 | 0.009418 |
INmune Bio Upcoming Company Events
As portrayed in its financial statements, the presentation of INmune Bio's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, INmune Bio's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of INmune Bio's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of INmune Bio. Please utilize our Beneish M Score to check the likelihood of INmune Bio's management manipulating its earnings.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with INmune Bio
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out INmune Bio Backtesting, INmune Bio Valuation, INmune Bio Correlation, INmune Bio Hype Analysis, INmune Bio Volatility, INmune Bio History and analyze INmune Bio Performance. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
INmune Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.